摘要
目的探讨生长抑素联用雷贝拉唑和恩替卡韦治疗老年乙型病毒性肝炎(简称乙肝)肝硬化伴上消化道出血的临床疗效。方法选取医院2022年6月至2024年9月收治的老年乙肝肝硬化伴上消化道出血患者96例,按随机数字表法分为观察组和对照组,各48例。两组患者均予雷贝拉唑和恩替卡韦,观察组患者在此基础上加用生长抑素。两组患者均连续治疗3 d。结果观察组患者的总有效率为93.75%,显著高于对照组的77.08(P<0.05);与对照组比较,观察组患者的输血量显著更少(P<0.05),止血时间和住院时间均显著更短(P<0.05)。治疗后,两组患者的血浆凝血酶原时间和部分凝血活酶时间均显著缩短(P<0.05),血小板和纤维蛋白原水平均显著升高(P<0.05),且观察组均显著优于对照组(P<0.05)。观察组和对照组患者治疗期间的再出血率及不良反应发生率均相当(2.08%比6.25%,6.25%比10.42%,P>0.05)。结论生长抑素联用雷贝拉唑和恩替卡韦治疗老年乙肝肝硬化伴上消化道出血的临床疗效良好,可减少患者的输血量,缩短止血时间和住院时间,改善凝血功能,且安全性良好。
Objective To investigate the clinical efficacy of somatostatin combined with rabeprazole and entecavir in the treatment of elderly patients with hepatitis B virus(HBV)-induced cirrhosis with upper gastrointestinal bleeding.Methods A total of 96 elderly patients with HBV-induced cirrhosis with upper gastrointestinal bleeding admitted to the hospital from June 2022 to September 2024 were selected and divided into the observation group and the control group by the random number table method,48 cases in each group.The patients in the two groups were treated with rabeprazole and entecavir,while the patients in the observation group were additionally treated with somatostatin.The two groups were continuously treated for 3 d.Results The total effective rate in the observation group was 93.75%,which was significantly higher than 77.08%in the control group(P<0.05).Compared with those in the control group,the blood transfusion volume in the observation group significantly reduced(P<0.05),and the hemostasis time and hospitalization time in the observation group significantly shortened(P<0.05).After treatment,the plasma prothrombin time and partial thromboplastin time in the two groups significantly shortened(P<0.05),while the average platelet and fibrinogen levels in the two groups significantly increased(P<0.05),and those in the observation group were significantly better than those in the control group(P<0.05).The incidence rates of rebleeding and adverse reactions during treatment were comparable between the observation group and the control group(2.08%vs.6.25%,6.25%vs.10.42%,P>0.05).Conclusion Somatostatin combined with rabeprazole and entecavir has a good clinical efficacy and safety in the treatment of elderly HBV-induced cirrhosis with upper gastrointestinal bleeding,which can reduce the blood transfusion volume,shorten the time of hemostasis and hospitalization,and improve the coagulation function.
作者
袁蓓
凌炜焱
田贞
吴迎凤
YUAN Bei;LING Weiyan;TIAN Zhen;WU Yingfeng(Rugao People′s Hospital,Nantong,Jiangsu 226500,China)
出处
《中国药业》
2026年第1期95-98,共4页
China Pharmaceuticals
基金
江苏省南通市市级科技计划(指导性)项目[MSZ19034]。
